A comprehensive assessment of the cholinergic‐supporting and cognitive‐enhancing effects of Rosa damascena Mill. (Damask rose) essential oil on scopolamine‐induced amnestic rats

Kerem Teralı,Dilek Ozbeyli,Duygu Yiğit‐Hanoğlu,Kemal Hüsnü Can Başer,Göksel Şener,Asli Aykac

DOI: https://doi.org/10.1002/brb3.3507

IF: 3.1

2024-05-02

Brain and Behavior

Abstract:Finding effective preventative and therapeutic solutions for the management of Alzheimer's disease (AD) should be urgent and important for researchers given the world's increasingly aging population. Despite the tragic rise in patients with AD globally, there is presently no viable cure or means to arrest the disease. Acetylcholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are used as part of the current treatment regimen but do not genuinely restore brain function in a clinical setting; instead, they just delay the advancement of AD. This places natural product research, which addresses various pathobiological processes tied to AD, at the center of anti‐AD drug discovery and development efforts. This is the first study to investigate the putative neuroprotective and pro‐cognitive activities of R. damascena essential oil against scopolamine‐induced amnesia of AD‐type in Wistar albino rats. Introduction Alzheimer's disease (AD) is a neurodegenerative condition characterized by gradual loss of cognitive abilities (dementia) and is a major public health problem. Here, we aimed at investigating the effects of Rosa damascena essential oil (RDEO) on learning and memory functions in a rat model of amnesia induced by scopolamine, as well as on changes in acetylcholinesterase (AChE) activity, M1 muscarinic acetylcholine receptor (mAChR) expression, and brain‐derived neurotrophic factor (BDNF) levels in the extracted brain tissues. Methods The control, amnesia (scopolamine, 1 mg/kg/i.p.) and treatment (RDEO, 100 μL/kg/p.o. or galantamine, 1.5 mg/kg/i.p.) groups were subjected to Morris water maze and new object recognition tests. AChE activity was assayed by ELISA, and M1 mAChR and BDNF concentration changes were determined by western blotting. Also, using computational tools, human M1 mAChR was modeled in an active conformation, and the major components of RDEO were docked onto this receptor. Results According to our behavioral tests, RDEO was able to mitigate the learning and memory impairments caused by scopolamine in vivo. Our in vitro assays showed that the observed positive effects correlated well with a decrease in AChE activity and an increase in M1 mAChR and BDNF levels in amnestic rat brains. We also demonstrated in an in silico setting that the major components of RDEO, specifically ‐citronellol, geraniol, and nerol, could be accommodated favorably within the allosteric binding pocket of active‐state human M1 mAChR and anchored here chiefly by hydrogen‐bonding and alkyl–π interactions. Conclusion Our findings offer a solid experimental foundation for future RDEO‐based medicinal product development for patients suffering from AD.

neurosciences,behavioral sciences